CIK 0000818033
- Accelerated filer
HERON THERAPEUTICS, INC. /DE/
Sign in to watch- Ticker
- HRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 942875566
- Phone
- +1 858-251-4400
- Business address
- 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- AP PHARMA INC /DE/, ADVANCED POLYMER SYSTEMS INC /DE/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-12-18 | MANHARD KIMBERLY Executive VP, Drug Development | Grant or award · Employee Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2017-12-18 | HOFFMAN ROBERT CFO & SVP, Finance | Grant or award · Employee Stock Option (Right to Buy) | +56,667 | 56,667 | ||
| 2017-10-31 | HOFFMAN ROBERT CFO & SVP, Finance | Other acquisition | +536 | $13.05 | $7K | 536 |
| 2017-04-28 | Quart Barry D Chief Executive Officer | Other acquisition | +1,684 | $12.62 | $21K | 67,993 |
| 2017-04-24 | MANHARD KIMBERLY Executive VP, Drug Development | Exercise or conversion | +5,250 | $8.80 | $46K | 5,250 |
| 2017-04-24 | MANHARD KIMBERLY Executive VP, Drug Development | Exercise or conversion | +16,292 | $9.05 | $147K | 21,542 |
| 2017-04-24 | MANHARD KIMBERLY Executive VP, Drug Development | Sale | −21,542 | $15.33 | $330K | 0 |
| 2017-04-24 | MANHARD KIMBERLY Executive VP, Drug Development | Exercise or conversion · Stock Option (Right to Buy) | −5,250 | 0 | ||
| 2017-04-24 | MANHARD KIMBERLY Executive VP, Drug Development | Exercise or conversion · Stock Option (Right to Buy) | −16,292 | 0 | ||
| 2017-04-24 | HOFFMAN ROBERT CFO & SVP, Finance | Grant or award · Employee Stock Option (Right to Buy) | +130,000 | 130,000 | ||
| 2017-04-05 | Christian Waage Director | Grant or award · Stock Option (Right to Buy) | +1,125 | 1,125 | ||
| 2017-01-19 | POYHONEN JOHN Director | Purchase | +10,000 | $12.20 | $122K | 10,000 |
| 2017-01-19 | TANG KEVIN C Director | Purchase | +2,459,016 | $12.20 | $30.0M | 8,332,907 |
| 2016-12-21 | Christian Waage Director | Grant or award · Stock Option (Right to Buy) | +15,500 | 15,500 | ||
| 2016-12-21 | POYHONEN JOHN Director | Grant or award · Stock Option (Right to Buy) | +19,500 | 19,500 | ||
| 2016-12-21 | Johnson Craig A Director | Grant or award · Stock Option (Right to Buy) | +21,000 | 21,000 | ||
| 2016-12-21 | Rosen Robert President | Grant or award · Employee Stock Option (Right to Buy) | +310,000 | 310,000 | ||
| 2016-12-21 | Quart Barry D Chief Executive Officer | Grant or award · Employee Stock Option (Right to Buy) | +310,000 | 310,000 | ||
| 2016-12-21 | TANG KEVIN C Director | Grant or award · Stock Option (right to buy) | +17,000 | 17,000 | ||
| 2016-12-21 | MANHARD KIMBERLY Executive VP, Drug Development | Grant or award · Employee Stock Option (Right to Buy) | +120,000 | 120,000 |
Page 34 of 38 · 746 trades